Overview

A Long-term Study of DE-117 Ophthalmic Solution Monotherapy and Concomitant Use of DE-117 Ophthalmic Solution With Timolol Ophthalmic Solution in Patients With OAG or OH: RENGE Study

Status:
Completed

Trial end date:
2017-11-09

Target enrollment:

Participant gender:

Summary

The purposes of this study are to evaluate the long-term safety and intraocular pressure-lowering efficacy of DE-117 ophthalmic solution monotherapy and concomitant use of DE-117 ophthalmic solution with timolol ophthalmic solution 0.5% in patients with open angle glaucoma or ocular hypertension.

Phase:

Phase 3

Details

Lead Sponsor:

Santen Pharmaceutical Co., Ltd.

Treatments:

Ophthalmic Solutions
Pharmaceutical Solutions
Timolol